CALM study: secondary endpoints of a phase II study of a novel oncolytic
immunotherapeutic agent, coxsackievirus A21, delivered intratumorally in patients with advanced malignant melanoma.
The immunotherapeutic agent Ipilumumab has been shown to have a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy.
«Our findings are encouraging, as they suggest that entolimod can be safely combined with other chemotherapeutic, targeted or
immunotherapeutic agents as treatment for advanced and very hard - to - treat cancers,» notes Dr. Adjei, who is Senior Vice President of Clinical Research and the Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park.
Several checkpoint inhibitors have been shown to be effective
immunotherapeutic agents.
Not exact matches
Immunotherapeutic concepts to target acute myeloid leukemia: focusing on the role of monoclonal antibodies, hypomethylating
agents and the leukemic microenvironment